Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy

Diabetologia

Volumn 44, Issue 11, 2001, Pages 1973-1988

  Cameron, N E ^a   Eaton, S E M ^b   Cotter, M A ^a   Tesfaye, S ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Advanced glycation; Aldose reductase; Blood flow; Diabetic neuropathy; Ischaemia; Microangiopathy; Nerve conduction; Nerve pathology; Nitric oxide; Oxidative stress; Protein kinase C; Vascular endothelium

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; NITRIC OXIDE; OMEGA 6 FATTY ACID; POLYOL; PROSTACYCLIN; PROTEIN KINASE C; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOVENOUS SHUNT; BASEMENT MEMBRANE; BLOOD FLOW; BLOOD VESSEL FUNCTION; DIABETIC NEUROPATHY; FATTY ACID METABOLISM; GLYCATION; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; METABOLISM; MICROANGIOPATHY; MICROVASCULATURE; NERVE CONDUCTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PERICYTE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

ANIMALS; DIABETIC ANGIOPATHIES; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; HUMANS; REGIONAL BLOOD FLOW; RISK FACTORS;

EID: 0035195970     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250100001     Document Type: Review

References (180)

1. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial
2. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33)
3. Improving the prognosis in type 2 diabetes: Diabetic neuropathy is in trouble
4. Diabetic neuropathies
5. Clinical manifestations and measurement of somatic neuropathy
6. Clinical features of diabetic neuropathy
7. Pain and diabetic neuropathy
8. Electrical spinal cord stimulation for painful diabetic peripheral neuropathy
9. Motor function in diabetes
10. Schwann-cell abnormalities in diabetic neuropathy
11. The spatial distribution of fibre loss in diabetic polyneuropathy suggests ischaemia
12. Foot problems in patients with diabetes mellitus
13. The epidemiology of diabetic neuropathy
14. The prevalence of diabetic peripheral neuropathy and it's relation to glycaemic control and potential risk factors: The EURODIAB IDDM complications study
15. A multicentre study on the prevalence of diabetic neuropathy in Italy: Italian Diabetic Neuropathy Group
16. End stage complications of diabetic neuropathy
17. Economic aspects of diabetic neuropathy and related diabetic complications
18. Costs and duration of care for lower extremity ulcers in patients with diabetes
19. Reduced microvascular hyperaemia in subjects at risk of developing type 2 (non-insulin dependent) diabetes mellitus
20. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes
21. Hypertension as a risk factor for diabetic neuropathy: A prospective study
22. Cardiovascular risk factors predict development of diabetic peripheral neuropathy
23. Is ACE inhibition with lisinopril helpful in diabetic neuropathy?
24. Effect of the angiotensin converting enzyme inhibitor trandalopril on human diabetic neuropathy: A randomised controlled trial
25. 2A receptor antagonist sarpogrelate in diabetic patients with complications - A pilot study
26. Epidemiological correlates of diabetic neuropathy. Report from the Pittsburgh Epidemiology of Diabetic Complications Study
27. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study
28. Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy
29. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes
30. Clinical and experimental studies on retinal neovascularisation
31. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
32. Glomerular hyperfiltration in human diabetes
33. Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy
34. Nerve blood flow in early experimental diabetes in rats: Relation to conduction defects
35. Vascular and metabolic factors in the pathogenesis of experimental diabetic neuropathy in mature rats
36. Sural nerve oxygen tension in diabetes
37. A new minimally invasive technique to show nerve ischaemia in diabetic neuropathy
38. Impaired blood flow and arterio-venous shunting in human diabetic neuropathy: A novel technique of nerve photography and fluoroscein angiography
39. Local human sural nerve blood flow in diabetic and other polyneuropathies
40. Skin capillary circulation severely impaired in toes of patients with IDDM, with and without late diabetic complications
41. Correlation between nerve function and tissue oxygenation in diabetic patients: Further clues to the aetiology of diabetic neuropathy?
42. Vascular insufficiency quantitatively aggrevates diabetic neuropathy
43. Restoring limb blood flow improves nerve function in diabetic patients
44. Exercise induced conduction velocity increment: A marker of impaired peripheral nerve blood flow in diabetic neuropathy
45. Hypoxic neuropathy: Relevance to human diabetic neuropathy
46. Nerve ischaemia resistance: An early change in diabetes mellitus
47. Is resistance to ischaemic conduction failure induced by hypoxia?
48. Studies of resistance to ischemic nerve conduction failure in normal and diabetic rats
49. Effects of chronic á-adrenergic receptor blockade on peripheral nerve conduction, hypoxic resistance, polyols. Na-K ATPase activity and vascular supply in streptozocin-diabetic rats
50. Pharmacological manipulation of vascular endothelium in non-diabetic and streptozotocin-diabetic rats: Effects on nerve conduction, hypoxic resistance and endoneurial capillarization
51. On diabetic neuritis with a clinical and pathological description of three cases of diabetic pseudo-tabes
52. Diabetic neuropathy: A clinical and histological study on the significance of vascular affections
53. Morphology of diabetic neuropathy
54. Microangiopathy in human diabetic neuropathy
55. Basement membrane thickening and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity
56. Endoneurial capillary abnormalities in mild human diabetic neuropathy
57. Microangiopathy in human diabetic neuropathy; relationship between capillary abnormalities and the severity of neuropathy
58. Relationship of endoneurial capillary abnormalities to type and severity of diabetic neuropathy
59. Pathologic alterations in human diabetic polyneuropathy
60. Abnormalities of endoneurial microvessels and sural nerve pathology in diabetic neuropathy
61. Endoneurial localisation of microvascular damage in human diabetic neuropathy
62. Pattern of myelinated fibre loss in sural nerve in neuropathy related to type 1 insulin-dependent diabetes
63. Clinical and histological studies in diabetic neuropathy
64. Electromicroscopical studies of vessels in diabetic neuropathy
65. Small vessel disease in progressive diabetic neuropathy associated with good metabolic control
66. Capillary number and percentage closed in human diabetic sural nerve
67. Platelet abnormalities in diabetic neuropathy
68. Reduced erythrocye deformability in diabetes
69. Increased adhesion of erythrocytes to endothelial cells in diabetes mellitus and its relation to vascular complications
70. Altered blood rheology in the pathogenesis of diabetic and other neuropathies
71. Relationship between haemstatic factors and capillary morphology in human diabetic neuropathy
72. The pathology of human diabetic neuropathy
73. Transperineurial arterioles in human sural nerve
74. Innervation of the vasa nervorum: Changes in human diabetics
75. Venous oxygenation in the diabetic foot: Evidence of arteriovenous shunting
76. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis)
77. The effect of occlusive arterial disease of the extremeties on the blood supply of the nerves: Experimental and clinical studies on the vasa nervorum
78. Microsphere embolization of nerve capillaries and fiber degeneration
79. Pathogenesis of diabetic neuropathy
80. Hypoxic effect of exogenous insulin on normal and diabetic peripheral nerve
81. Sural nerve haemodynamics in painful and painless neuropathy: Clues to the cause of pain?
82. Diabetic third nerve palsy: Evidence for a mesencephalic lesion
83. Oculomotor palsy in diabetes mellitus: A clinicopathological study
84. The pupilloconstrictor pathway and the nerves to the ocular muscles in man
85. Early and preventable changes of peripheral nerve structure and function in insulin-deficient diabetic rats
86. The effects of Sorbinil on peripheral nerve conduction velocity, polyol concentrations and morphology in the streptozotocin diabetic rat
87. Neurons undergo apoptosis in animal and cell culture models of diabetes
88. Peripheral neuropathy following prolonged exposure to streptozotocin induced diabetes in rats: A teased fiber study
89. Pathology and pathogenetic mechanisms of diabetic neuropathy
90. Experimental diabetic neuropathy: An update
91. New therapeutic approaches to prevent or halt the progression of the longterm complications of diabetes mellitus: Focus on neuropathy
92. Neuropathology and blood flow of nerve, spinal roots and dorsal root ganglia in longstanding diabetic rats
93. 1 receptor antagonist
94. The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications
95. Responses of the skin microcirculation to acetylcholine and sodium nitro-prusside in patients with NIDDM
96. Differences in foot and forearm skin microcirculation in diabetic patients with and without neuropathy
97. Review of alterations in endothelial nitric oxide production in diabetes: Protective role of arginine on endothelial dysfunction
98. Impairment of endothelium-dependent relaxation and changes in levels of cyclic GMP in aorta from streptozotocin-induced diabetic rats
99. Alterations in endothelium-dependent hyperpolarization and relaxation of mesenteric arteries from reptozotocin-induced diabetic rats
100. Effects of aldose reductase inhibition on responses of the corpus cavernosum and mesenteric vascular bed of diabetic rats
101. Impaired vasoreactivity to nitric oxide in experimental diabetic neuropathy
102. Effect of diabetes on reactivity of sciatic vasa nervorum in rats
103. Prostacyclin and noradrenaline in peripheral nerve of chronic experimental diabetes in rats
104. Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition
105. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood fiow and oxygen tension in non-diabetic and streptozotocin-diabetic rats
106. Elevated serum angiotensin I converting enzyme activity in type 1, insulin-dependent diabetic subjects with persistent microalbuminuria
107. Production of endothelin-1 from the mesenteric arteries of streptozotocin-induced diabetic rats
108. Elevated plasma endothelin levels in patients with diabetes mellitus
109. Regulatory effect of experimental diabetes on the expression of endothelin receptor subtypes and their gene transcripts in the rat adrenal gland
110. The potential role of cell adhesion molecules in the pathogenesis of diabetic neuropathy
111. Angiotensin converting enzyme inhibition prevents the development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats
112. The potential contribution of endothelin-1 to neurovascular abnormalities in streptozotocin-diabetic rats
113. A antagonist on neurovascular function in diabetic rats: Interaction with the renin-angiotensin system
114. 1 adrenoceptor antagonist treatment: Interactions with the nitric oxide system
115. 1-adrenoceptor antagonist on diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense
116. The effect of the calcium antagonist nifedipine on peripheral nerve function in streptozotocin-diabetic rats
117. 2+ antagonist, nimodipine, on an existing neuropathy in the streptozotocin-induced, diabetic rat
118. Effects of beraprost sodium and insulin on the electroretinogram, nerve conduction and nerve blood flow in rats with streptozotocin-induced diabetes
119. 1 analogue TFC 612 on diabetic neuropathy in streptozocin-induced diabetic rats comparison with aldose reductase inhibitor ONO 2235
120. Effects of chronic treatment with a nitric oxide donor on nerve conduction abnormalities and endoneurial blood fow in streptozotocin-diabetic rats
121. + ATPase, and glutathione in diabetic rats
122. Effect of cilostazol on experimental diabetic neuropathy in the rat
123. Effects of cilostazol, an antiplatelet agent, on axonal regeneration following nerve injury in diabetic rats
124. A receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain
125. Complications: Neuropathy, pathogenetic considerations
126. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm
127. Diabetes mellitus and free radicais
128. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy
129. Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes
130. Effects of insulin and oral glutathione on glutathione leveis and superoxide dismutase activities in organs of rats with streptozotocin-induced diabetes
131. Diabetic endothelial dysfunction: The role of poly(ADP-ribose) polymerase activation
132. Increased nitrotyrosine in the diabetic placenta - Evidence for oxidative stress
133. Generation of reactive oxygen intermediates, activation of NFkappa B, and induction of apoptosis in human endothelial cells by glucose: Role of nitric oxide synthase?
134. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide
135. Chronic vitamin E treatment prevents defective endothelium relaxation in diabetic rat aorta
136. Endothelial relaxation is disturbed by oxidative stress in the diabetic rat heart: Infiuence of tocopherol as antioxidant
137. Contraction and relaxation of aortas from diabetic rats: Effects of chronic anti-oxidant and aminoguanidine treatments
138. Vitamin C improves endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus
139. Impaired endothelium-derived hyperpolarizing factor in the mesenteric vasculature of diabetic rats: Effects of antioxidant treatment
140. Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy
141. Effects of natural free radical scavengers on peripheral nerve and neurovascular function in diabetic rats
142. Effects of α-lipoic acid on neurovascular function in diabetic rats: Interaction with essential fatty acids
143. Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with n-acetylcysteine
144. Effects of α-tocopherol on nerve conduction velocity and regeneration following a freeze lesion in immature diabetic rats
145. Effect of diabetes and treatment with the antioxidant, α-lipoic acid, on endothelial and neurogenic responses of corpus cavemosum in rats
146. Long-term treatment in vivo with NOX-101, a scavenger of nitric oxide, prevents diabetes-induced endothelial dysfunction
147. Selective nitrergic neurodegeneration in diabetes mellitus - A nitric oxide-dependent phenomenon
148. Rapid reversal by aminoguanidine of the neurovascular effects of diabetes in rats: Modulation by nitric oxide synthase inhibition
149. Interactions between essential fatty acid, prostanoid, polyol path-way and nitric oxide mechanisms in the neurovascular deficit of diabetic rats
150. +-ATPase activity and glutathione content in diabetic rats
151. Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity
152. Impaired endothelium-dependent and -independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: Role of dyslipidaemia
153. Preservation of endothelium-dependent relaxation in cholesterol-fed and streptozotocin-induced diabetic mice by the chronic administration of cholestyramine
154. Effects of treatment with the statin, ZD4522, on peripheral nerve function and perfusion in diabetic rats
155. Altered tissue content and cytosol distribution of trace metais in experimental diabetes
156. Copper, zinc, manganese, and magnesium status and complications of diabetes mellitus
157. Neurovascular deficits in diabetic rats: Potential contribution of autoxidation and free radicals examined using transition metal chelating agents
158. Effects of chelator treatment on aorta and corpus cavernosum from diabetic rats
159. Effects of an extracellular metal chelator on neurovascular function in diabetic rats
160. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: A 7-month multicenter randomized controlled trial (ALADIN III Study)
161. Advanced glycosylation end products in diabetic complications. Biochemical basis and prospects for therapeutic intervention
162. Protein aging by carboxymethylation of lysines generates sites for divalent metal and redox active copper binding: Relevance to diseases of glycoxidative stress
163. Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: Implications for advanced glycation and diabetic complications
164. New approaches for treatment in diabetes: Aldose reductase inhibitors
165. Minalrestat
166. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy
167. Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: Dose-response considerations and independence from a myo-inosftol mechanism
168. Evaluation of a sorbitol dehydrogenase inhibitor on diabetic peripheral nerve metabolism: A preventive study
169. Spirohydantoin inhibitors of aldose reductase inhibit iron-catalyzed and copper catalyzed ascorbate oxidation in vitro
170. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats
171. Effect of sorbitol dehydrogenase inhibition on experimental diabetic autonomic neuropathy
172. Protein kinase C activation and the development of diabetic complications
173. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats
174. Effects of the diacylglycerol complexing agent, cremophor, on nerve conduction velocity and perfusion in diabetic rats
175. Treatment with the protein kinase Cβ inhibitor, LY333531, attenuates the development of impaired endothelium-dependent vasodilatation in the mesenteric vasculature of diabetic rats
176. Role of linolenic acid in diabetic polyneuropathy
177. Effects of dietary supplementation with arachidonic acid rich oils on nerve conduction and blood flow in streptozotocin-diabetic rats
178. Essential fatty acid effects on endothelium dependent relaxation in the mesenteric vascular bed of diabetic and nondiabetic rats
179. Cytochrome P450 2C is an EDHF synthase in coronary arteries
180. Comparison of the effects of ascorbyl γ-1inolenic acid and γ-1inolenic acid in the correction of neurovascular deficits in diabetic rats